There's a considerable amount of attention being focused on Exelixis' move to launch a late-stage study of XL184. The Motley Fool says that the first stage of the trial should be wrapped by the end of next year, giving investors a key point to decipher the drug's commercial prospects. That could mean an approval and marketing as early as 2010, but the Fool is quick to note that that is only a very rough timeline.
- see Exelixis' release
- read the analysis from Motley Fool